New personalized medicine model could lead to better care, lower costs, higher profits

January 15, 2009

Cambridge consulting firm Scientia Advisors says that big pharma could begin to reap profits from personalized medicine much sooner than predicted by marketing new diagnostics tools along with drugs that are already on the market. (Most pharma companies are currently using personalized medicine tools only in developing new drugs–which won’t bring any profits for years down the road).  Based on quantitative and qualitative research, Scientia’s study, published in the January, 2009 Pharmaceutical Executive describes how  three companies grew their profits and improved their relationships with prescribing physicians using the new model.  According to Scientia Managing Partner Harry Glorikian, the method will also improve patient care, lower costs and lead to health system reforms.  More info is available at

Scientia Advisors is a client of the Harris Communications Group.

Anita Harris


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: